Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.45 |
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31301568 | 0.89 | GPBAR1 (0.54) | MLYCDHDAC1KDM1AGPBAR1LIPE | |
| SCHEMBL31301548 | 0.84 | SCN10A (0.54) | HDAC1GPBAR1SCN10AHSD17B1HSD17B2 | |
| SCHEMBL31301583 | 0.82 | GPBAR1 (0.47) | MLYCDHDAC1KDM1AGPBAR1LIPE | |
| SCHEMBL31301417 | 0.78 | MAP4K4 (0.52) | GPBAR1SCN10A | |
| SCHEMBL13876033 | 0.75 | KDM1A (0.54) | HDAC1KDM1ASCN10A | |
| SCHEMBL31301420 | 0.75 | MKNK1 (0.62) | HDAC1KDM1A | |
| SCHEMBL1843427 | 0.75 | MKNK1 (0.62) | HDAC1KDM1A | |
| SCHEMBL640848 | 0.74 | MKNK1 (0.60) | HDAC1KDM1A | |
| SCHEMBL30108269 | 0.74 | MKNK1 (0.60) | HDAC1KDM1A | |
| SCHEMBL640445 | 0.73 | CYP11B1 (0.58) | HDAC1KDM1ASCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | SUB1, PFN1, HCCS | MLYCD 2142/4885HDAC1 1273/4885KDM1A 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.